Read on Twitter
Effect of Finerenone on CKD outcomes in T2DM
Finerenone decreased risk of CKD progression by 18%Finerenone decreased CV morbidity & mortality by 14%Published in @NEJM today
https://www.nejm.org/doi/full/10.1056/NEJMoa2025845?query=RP
@ASNKidney #Kidneywk
How does Finerenone work? (These Slides are from the ASN Kidney Week: High Impact Clinical Trial Session)
Trial eligibility criteria
Study Design
Baseline Demographics & Medications
Baseline eGFR and UACR
Change in UACR: 31% reduction with Finerenone at 4 months versus placebo
BP and HbA1c changes in the Finerenone and placebo groups
18% reduction in the Primary Kidney Composite Endpoint in the Finerenone group versus the Placebo group (p = 0.0014)
Numbers Needed to Treat (NNT)for Primary and Secondary endpoints over 3 years
Adverse Events and Change in Serum Potassium over time
Adverse events related to Hyperkalemia such as permanent drug discontinuation, hospitalization and death
Adverse events related to Acute Kidney Injury
Safety Summary of Finerenone
How drug discontinuation due to Hyperkalemia in FIDELIO-DKD Trial compare to the ALTITUDE & VA-NEPHRON-D Trials where dual RAS Blockade was used in DKD populations?
How did drug discontinuation due to Hyperkalemia in FIDELIO-DKD Trial compare to the AMBER Trial where Patiromer was used with Spironolactone + ACEi/ARB in CKD population?
